Physician profile
Lauri Shebesh
NPI 1558870790
$14,994.61
in general payments reported to CMS, 2019-2025
45 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $2,507 · 2023: $5,045 · 2024: $5,669 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,929 · Travel and Lodging: $5,274 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,929.41 |
| Travel and Lodging | $5,274.37 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $4,472.30 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $1,910.40 | 2022-2023 | Synchromedii, Percept PC Brainsense |
| Abbvie INC. | $1,820.84 | 2022-2025 | |
| Boston Scientific Corporation | $1,212.39 | 2021-2024 | |
| Abbott Laboratories | $1,180.70 | 2024-2025 | Infinity |
| Ucb, INC. | $681.95 | 2021-2025 | Rystiggo, Briviact, Fintepla |
| Pfizer INC. | $504.87 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $338.52 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $338.33 | 2022-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $234.29 | 2022 | |
| Sumitomo Pharma America, INC. | $194.43 | 2023-2024 | Aptiom |
| Emd Serono, INC. | $186.49 | 2021-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $183.94 | 2023-2025 | Rytary, Lyvispah, Crexont |
| Sk Life Science, INC. | $167.48 | 2022-2025 | |
| Genentech USA, INC. | $146.15 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $141.05 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $139.71 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $100.70 | 2023-2025 | Dysport |
| Kyowa Kirin, INC. | $98.55 | 2021-2024 | Nourianz |
| Celgene Corporation | $88.12 | 2022-2025 | Zeposia |
| Biogen, INC. | $75.72 | 2021-2024 | Skyclarys |
| Lilly USA, LLC | $71.62 | 2023-2024 | Amyvid, Kisunla |
| Amgen INC. | $68.57 | 2021-2025 | Aimovig, Uplizna |
| Acadia Pharmaceuticals INC | $63.80 | 2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $63.45 | 2023-2024 | Ultomiris |
| Argenx US, INC. | $60.89 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Alnylam Pharmaceuticals INC. | $47.01 | 2022-2023 | Onpattro |
| Supernus Pharmaceuticals, INC. | $39.12 | 2022 | |
| Jazz Pharmaceuticals INC. | $38.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.11 | 2021 | |
| Axsome Therapeutics, INC. | $26.84 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $26.49 | 2023 | |
| Avion Pharmaceuticals | $25.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.17 | 2023 | Rexulti |
| Adamas Pharmaceuticals, INC. | $23.94 | 2021 | |
| Microtransponder, INC. | $22.70 | 2025 | |
| Eisai INC. | $21.48 | 2023 | |
| Aucta Pharmaceuticals, INC. | $18.90 | 2024 | Motpoly Xr |
| Zoll Respicardia, INC. | $17.72 | 2023 | Remede System |
| Cycle Pharmaceuticals INC | $17.12 | 2025 | Tascenso Odt |
| Tanabe Pharma America, INC. | $15.42 | 2024 | |
| Ani Pharmaceuticals, INC. | $15.16 | 2023 | Purified Cortrophin Gel |
| Mdd US Operations, LLC | $14.48 | 2024 | Apokyn |
| Ge Healthcare | $13.54 | 2023 | |
| Corium, LLC | $11.17 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauri Shebesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.